Punjab Chemicals & Crop Protection Ltd

- The transcript does not mention any current or immediate plans for new fundraising through debt or equity. - The company has a debt-equity ratio of around 0.32 with a sanctioned working capital limit of over Rs. 100 crores, but utilization is not fully maxed out (around Rs. 60 crores utilized). - CAPEX plans for the year are focused on maintenance (Rs. 35-40 crores) and potential new manufacturing blocks (Rs. 45-50 crores) depending on customer commitments. - The company is cautious and awaiting clearer customer demand indications before committing to larger expansions, suggesting no urgent need for fresh fundraising at this time. - Any decisions on new sites or large-scale expansion (greenfield or brownfield) will be communicated when finalized; currently, site scouting is ongoing without confirmed acquisitions. In summary, no explicit current plans for raising funds via debt or equity have been announced.

- **Current FY Capex:** Rs. 35-40 crores mainly for maintenance and small additions (Page 12). - **New Manufacturing Block:** Plan to invest an additional Rs. 45-50 crores for a new manufacturing block once long-term contracts and clearer customer demand materialize (Page 12). - **Total Capex Outlook:** Around Rs. 100 crores when combining maintenance and expansion capex (Page 12). - **Greenfield/Brownfield Site Search:** Actively scouting for a new site (greenfield or brownfield) mainly for agrochemicals to support future growth (Pages 11, 15). - **Pune Unit Expansion:** Exploring a new site due to increasing food-grade acid demand; current capacity sufficient for existing customers (Page 15). - **R&D Expansion:** Investing in strengthening R&D facilities by adding reactors, space, and hiring professionals to develop new chemistries and increase product complexity (Page 14).

- Sales and revenue are expected to improve starting Q2 and Q3 of FY ’25, with better market conditions and new product launches (Page 9, 13). - FY ’26 is anticipated to be a far better year compared to FY ’24 and FY ’25, driven by normalized demand and increased volumes (Page 7, 8, 9). - Volumes have mostly remained stable quarter-on-quarter, with some growth expected as channel inventories destock (Page 12). - New molecules/products contributing 6-8% currently are projected to grow significantly, targeting 20% of top line from new products in the next two years (Page 5, 6). - Capacity utilization at plants is expected to increase, with Derabassi plant utilization rising above current 79%, and Lalru moving from 52% towards 60-65% this year (Page 12). - Market demand, especially domestic and international (Europe, US, Latin America), to improve as inventory levels normalize and prices correct upward by 4-6% over 18-24 months (Page 13, 14).

- The company expects a better market environment and improved earnings from FY ‘26 onward as demand recovers and inventory destocking eases. - New products commercialization and ramp-up, particularly from FY ‘25 H2 and FY ‘26, are expected to enhance revenue and margins. - Expansion in R&D capabilities and addition of new chemistries are expected to strengthen product portfolio, boosting higher value product sales. - Gross margins are anticipated to improve beyond the current ~39%, targeting around 40%+ as new higher-margin products scale up. - CAPEX of around Rs. 35-40 crores planned for maintenance with an additional Rs. 45-50 crores earmarked for new manufacturing blocks, supporting growth. - New molecules target contributing 20% of top-line over next two years, indicating growth in specialty products with better margins. - EBITDA margin in Q1 was impacted by one-off expenses, expected to normalize, supporting operating profitability growth. - Overall, FY ‘26 is expected to be a better year compared to FY ‘24 and FY ‘25.

- The company has a good order book visibility for the next 2 to 3 quarters. - The new molecules and products have started to roll out, but ramp-up is cautious due to current market sentiment. - One commercial product's order book is secured till the year-end; wider volume growth expected post channel inventory liquidation starting Q1 next year. - The company anticipates sales and revenue rise in Q2, Q3, and Q4 with new product launches. - Inventory destocking expected by Q3, facilitating better order flow and market normalcy. - Long-term contracts with multinational customers like BASF indicate stable, ongoing orders. - Management is monitoring market signals, waiting for positive indications before capacity expansion for newer products.